Research
Hormonal
Obstructive Sleep Apnea is causally linked to the development of systemic hypertension, with worsening AHI independently associated with an increasing risk of new hypertension, even in mild cases.
Even mild sleep apnea can silently raise your risk of developing high blood pressure. If you have risk factors like obesity or snoring, getting screened for sleep apnea is important for your long-term heart health, regardless of whether you feel tired during the day.
StrongSupportsVERY_HIGH confidence
The most compelling evidence that obstructive sleep apnea is causally related to cardiovascular disease comes from the Wisconsin Sleep Cohort Study (72). In normotensive persons who were followed for 4 years after an initial sleep study, worsening severity of obstructive sleep apnea was independently associated with progressively increasing risk for new hypertension... Even persons with very mild abnormalities in the apnea– hypopnea index (0.1 to 4.9) had 42% greater odds of developing hypertension at follow-up than did those with an apnea– hypopnea index of 0.
Why this rating
Based on longitudinal cohort studies with rigorous methods, described as 'most compelling evidence'.
Source
Obstructive Sleep Apnea
Sean M. Caples et al. · Annals of Internal Medicine · 2005
DOI 10.7326/0003-4819-142-3-200502010-00010
narrative_reviewCited 449×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Continuous positive airway pressure (CPAP) therapy effectively reverses sleep-related disordered breathing and daytime symptoms, and mitigates acute pathophysiologic responses such as sympathetic activation and endothelin elevation, though long-term cardiovascular mortality benefits remain unproven.Good
- Weight loss of approximately 10% in overweight patients with OSA leads to clinically significant improvement in the Apnea-Hypopnea Index, although it rarely normalizes the index completely.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →